The spinal cord is a vital part of the central nervous system that carries signals between the brain and the rest of the body. It controls movement, coordination, reflexes, and sensation. In dogs affected by ENM, a genetic defect leads to progressive damage of spinal cord neurons and supporting tissues. Over time, this results in impaired signal transmission, causing worsening neurological dysfunction.
Clinical signs of ENM typically appear in young dogs or early adulthood, depending on breed and mutation severity. Early symptoms may include mild hind limb weakness, unsteady gait (ataxia), or reduced coordination. As the disease progresses, neurological deficits become more severe, often starting in the hind limbs and gradually affecting the entire body.
Affected dogs may show difficulty rising, dragging of the hind legs, and loss of balance during movement. Muscle wasting (atrophy) may develop due to reduced nerve stimulation. Reflexes may become diminished or absent, and mobility gradually declines. In advanced stages, dogs may lose the ability to walk and require assistance for basic movement and care.
Unlike inflammatory spinal diseases, ENM is non-inflammatory and degenerative, meaning it results from progressive nerve tissue destruction rather than infection or immune-mediated attack. The condition is irreversible and typically worsens over time as more spinal cord tissue becomes affected.
The ENM DNA Health Test is designed to detect the specific genetic mutation responsible for Hereditary Necrotising Myelopathy. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Because genetic information remains unchanged throughout life, testing can be performed at any age, including before clinical signs appear.
Results are generally reported as:
- Clear (Normal): The dog does not carry the ENM mutation and is not expected to develop or pass on the disease.
- Carrier: The dog carries one copy of the mutation but typically does not show clinical signs. However, it can pass the mutation to offspring.
- Affected/At Risk: The dog carries two copies of the mutation and is expected to develop progressive spinal cord degeneration associated with ENM.
Genetic testing for ENM is highly important for breeders, veterinarians, and dog owners. Breeders can use results to avoid carrier-to-carrier matings, significantly reducing the incidence of this severe neurological disorder while maintaining genetic diversity within breeding populations.
For dog owners, knowing a dog’s genetic status allows for early monitoring and supportive care planning. While there is currently no cure for ENM, supportive management such as physiotherapy, mobility assistance, pain management, and environmental adaptations can help maintain comfort and quality of life for affected dogs. Regular neurological evaluations are essential to monitor progression.
The Hereditary Necrotising Myelopathy (ENM) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited spinal cord disorder in future generations.
